Novonesis (NSIS) AGM 2021 summary
Event summary combining transcript, slides, and related documents.
AGM 2021 summary
26 Oct, 2026Board and executive committee updates
Jørgen Buhl Rasmussen was re-elected Chair and Cornelis (Cees) de Jong Vice Chair; Heine Dalsgaard, Sharon James, Kasim Kutay, Kim Stratton and Mathias Uhlén were re-elected as Board members.
The Board also includes employee representatives Anne Breum, Anders Hentze Knudsen, Preben Nielsen and Jens Øbro.
Dividend announcements
FY2020 profit distribution included a dividend of DKK 5.25 per DKK 2 share, unchanged compared with 2019.
Corporate governance
Shareholders approved the 2020 remuneration report, Board remuneration and the amended remuneration policy.
PricewaterhouseCoopers was re-elected as auditor.
Authorizations were renewed for the Board to implement capital increases and approved for treasury-share purchases and fully electronic annual shareholder meetings.
Shareholders approved a reduction of share capital to DKK 564,000,000.
Latest events from Novonesis
- 9M organic growth reached 7% and margin 37.9%; Human Health weakness and investment weighed.NSIS
Q3 2026 - 2021 report approved; dividend rose 5%, and Morten Sommer joined the Board.NSIS
AGM 2022 - A DKK 6.00 dividend and key Board and governance resolutions were approved.NSIS
AGM 2023 - Shareholders approved a secondary name and elected four Board leaders.NSIS
EGM 2024 - Raised full-year sales growth outlook to 7-8% after 8% organic growth and EUR 1bn buyback.NSIS
Q2 2026 - Strong 2024 results; shareholders approved the dividend, elections, and key authorizations.NSIS
AGM 2025 - Diversification and innovation support biofuel growth and emerging SAF opportunities.NSIS
Status Update - 2024 outlook upgraded with higher growth and margins, driven by innovation and synergies.NSIS
CMD 2024 - 11% organic sales growth, margin expansion, and a major acquisition highlight Q1 2025.NSIS
Q1 2025